Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
8
×
deals
8
×
life sciences
national blog main
san diego blog main
san diego top stories
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston top stories
startups
alzheimer's disease
cancer
cancer immunotherapy
novartis
pfizer
clinical trials
gilead sciences
medicare
merck
roche
What
bio
roundup
drug
companies
acquisitions
alzheimer’s
billions
biogen’s
ceo
crispr
gene
life
nash
news
patients
price
science
sciences
talk
aducanumab
albert
alliance
amyloid
angst
announced
approval
awards
bagged
becker
biggest
biogen
biopharmaceutical
bourla
brammer
bristol
buy
calls
changing
collabs
color
Language
unset
unknown
Current search:
biogen
×
deals
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
Meet the Xconomy Awards San Diego Digital Trailblazer Finalists
@xconomy.com
4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More